sameAs
P3781
Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by SurgeryInvestigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212Dabrafenib, Trametinib, and Navitoclax in Treating Patients With BRAF Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryNeoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive MelanomaDabrafenib and Trametinib in Patients With Non-small Cell Lung Cancer Harboring V600E BRAF MutationEfficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular EventSelumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or DabrafenibStudy of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-sA Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid TumorsDetermination of the Absolute Bioavailability of GSK2118436 Following a Single Oral Dose Co-Administered With an Intravenous Radiolabelled Microtracer of GSK2118436 in Subjects With BRAF Mutant Solid TumorsA Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive TumorsAn Open Label Study to Examine the Effects of a High-Fat Meal and Particle Size on the Pharmacokinetics of Orally Administered GSK2118436 in Subjects With BRAF Mutation Positive TumorDabrafenib + Trametinib + PDR001 In Colorectal CancerA Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant MelanomaDabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 MelanomaA Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant MelanomaDabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 MutationsCAcTUS - Circulating Tumour DNA Guided SwitchTargeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)MOLECULAR PROFILING OF ADVANCED SOFT-TISSUE SARCOMASDabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant MelanomaDabrafenib and/or Trametinib Rollover StudyConcurrent Dabrafenib and Trametinib With Sterotactic Radiation in Patients With BRAF Mutation-Positive Malignant Melanoma and Brain MetastasesNeoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III MelanomaPhase II Pediatric Study With Dabrafenib in Combination With Trametinib in Patients With HGG and LGGA Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal CancerDabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D MelanomaJSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations
P4844
Panitumumab / Dabrafenib / Trametinib combination therapyDabrafenib / Trametinib combination therapyPanitumumab / Dabrafenib / BYL719 combination therapydabrafenib / Panitumumab combination therapyvemurafenib / dabrafenib combination therapytrametinib / vemurafenib / dabrafenib combination therapyMelanoma
P527
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Dabrafenib
@de
Dabrafenib
@nb
Dabrafenib
@sh
Dabrafenib
@sr
dabrafenib
@cs
dabrafenib
@en
dabrafenib
@fr
dabrafenib
@nn
дабрафениб
@ru
دابرافينيب
@ar
type
label
Dabrafenib
@de
Dabrafenib
@nb
Dabrafenib
@sh
Dabrafenib
@sr
dabrafenib
@cs
dabrafenib
@en
dabrafenib
@fr
dabrafenib
@nn
дабрафениб
@ru
دابرافينيب
@ar
altLabel
DRB436
@en
Dabrafenib
@en
GSK2118436
@en
GSK2118436A
@en
Tafinlar
@cs
Tafinlar®
@en
prefLabel
Dabrafenib
@de
Dabrafenib
@nb
Dabrafenib
@sh
Dabrafenib
@sr
dabrafenib
@cs
dabrafenib
@en
dabrafenib
@fr
dabrafenib
@nn
дабрафениб
@ru
دابرافينيب
@ar